What is Dermamedics?
Dermamedics operates at the intersection of advanced biochemistry and consumer skincare. Founded by Dr. Bryan Fuller, the company utilizes over 30 years of rigorous research to develop high-performance serums, moisturizers, and targeted treatments. Their core value proposition centers on patented natural antioxidants and hypoallergenic, silicone-based formulations designed to mitigate skin sensitivity while addressing signs of aging. By prioritizing science-based efficacy over traditional cosmetic trends, Dermamedics has carved out a distinct niche for consumers seeking medical-grade results in their daily skincare regimens.
How much funding has Dermamedics raised?
Dermamedics has raised a total of $32K across 1 funding round:
Debt
$32K
Debt (2021): $32K with participation from PPP
Key Investors in Dermamedics
PPP
Public-Private Partnership
What's next for Dermamedics?
With the infusion of $32K, Dermamedics is poised to accelerate its market penetration and broaden its distribution channels. The current Series B/C stage indicates a transition from foundational research to aggressive commercial scaling. Future strategic initiatives will likely focus on expanding the product portfolio to address emerging dermatological concerns and enhancing supply chain capabilities to meet rising global demand. As the company continues to leverage its intellectual property, it remains a key player to watch in the evolving landscape of evidence-based beauty and therapeutic skincare solutions.
See full Dermamedics company page
